In today's fool....https://www.fool.co.uk/2025/01/15/3-key-reasons-why-astrazenecas-share-price-looks-a-steal-to-me-right-now/ |
Selkirk,
It's beyond farce in the US litigation side. And it gets worse depending on the State one is in. |
GeckoAgree, if that was the case, I'd be claiming, at least, a million £££ back, over the years, lol. It's the US... If they can find blame, it's a claim. Surely there's no mileage in this. |
AZN INVESTOR DEADLINE: AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Jan 13 2025 14:15 GMT
SAN DIEGO , Jan. 13, 2025 /PRNewswire/
--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period"), have until February 21, 2025 to seek appointment as lead plaintiff of the AstraZenecaclass action lawsuit.
Captioned Saleh v. AstraZeneca PLC, No. 24-cv-11021 (C.D. Cal.), the AstraZenecaclass action lawsuit charges AstraZeneca as well as certain of AstraZeneca's top executives with violations of the Securities Exchange Act of 1934. |
What is today's news?
Cant see anything Astra Zeneca specific. |
With today's news who cares what's happening in China . |
Lawyers ...
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman |
AstraZeneca sees sales slump in China after arrest of exec -
(Alliance News) - Sales in China have suffered for AstraZeneca PLC
after the arrest of its country president, the Financial Times reported on Wednesday,
citing "two people familiar with the matter".
Executives at the Cambridge, England-based pharmaceuticals maker expect
an "evident" hit to revenue in China, following the arrest of Leon Wang
and other company executives, the newspaper reported.
Sales of oncology products, at the centre of the investigation by Chinese
authorities, have been hurt in particular, the FT said, as local hospitals
shun buying Astra's drugs. |
Whist maintaining a 'buy' rating. |
That's the only news out there on AZN.
"AstraZeneca (AZN.L)slipped 2.7% to the bottom of the blue-chip index after HSBC analysts cut the target price on the drugmaker's stock to 13,720p from 14,070p." |
Any idea why this is 3% Down or more overhang from China? |
AstraZeneca today announced the appointment of Iskra Reic as Executive Vice President (EVP), International with responsibility for overall strategy and driving sustainable growth across this broad region.
This encompasses China, Asian and Eurasian markets, Middle East & Africa, Latin America, Australia & New Zealand.
Iskra succeeds Leon Wang who is on extended leave from the Company while under investigation in China. |
benralizumab first new treatment for Asthma and COPD for 50 years and injection every 4 to 8 weeks looks like a game changer to me .
AZN share price is sure to fall today
Edit
. benralizumab/Fasenra looks to have been in phase 3 trials since 2013 why would it take so long ,or has there been some improvements made in benralizumab /Fasenra .
cost seems a little high $5197 per ml
It was approved by US and EU regulators in 2017 but just 7 years later they find that its by injection that it can stop severe asthma and COPD attacks 4 times better than the standard steroid treatment.Better late than never I would say. |
Price (GBX)
10,474.00 -% (-)
Open / Last close
10,484.00 / 10,474.00
High / Low
10,546.00 / 10,404.00
Bid / Offer
10,474.00 / 10,476.00
Special Condition: -
Trading Status: Normal - Closed
FTSE 100
As at 25.11.24 20:36:09 GMT
LSE |
ASTRAZENECA : Goldman Sachs reaffirms its Buy rating
November 25, 2024 at 12:33 pm
Rajan Sharma from Goldman Sachs retains his positive opinion on the stock with a Buy rating. The target price is unchanged and still at GBX 15955. |
The UK stock market never fails to amaze me down 4p on this news,Hope top management actually start to think about this nonsense and move the listing to the US it must be blatantly obvious to them that the UK is not the place for AZN .
If this was a US listed company do you think that the share price would react in this manner.
Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally.1 |
The UK stock market never fails to amaze me down 4p on this news,Hope top management actually start to think about this nonsense and move the listing to the US it must be blatantly obvious to them that the UK is not the place for AZN .
If this was a US listed company do you think that the share price would react in this manner.
Prostate cancer is the second most prevalent cancer in men and the fifth leading cause of male cancer death globally.1 |
JP Morgan Cazenove out with strong buy this morning with £140 share price forecast. |
Slowly creeping up.Mkt obvs forgotton abt China |
Non Exec director purchase stateside
3,000 @ USD 63.398167 = $190,000 |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
